Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and disease    2019, Vol. 10 Issue (3) : 601-610     DOI: 10.14336/AD.2018.0615
Orginal Article |
Mitochondrial Creatine Kinase is Decreased in the Serum of Idiopathic Parkinson’s Disease Patients
Jinghui Xu1, Xiaodi Fu1, Mengqiu Pan2, Xiao Zhou1, Zhaoyu Chen3, Dongmei Wang1, Xiaomei Zhang1, Qiong Chen1, Yanhui Li1, Xiaoxian Huang1, Guanghui Liu1, Jianjun Lu2, Yan Liu4, Yafang Hu1, Suyue Pan1, Qing Wang3, Qun Wang1,*, Yunqi Xu1,*
1Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China
2Department of Neurology, Guangdong 999 Brain Hospital, Guangzhou, China
3Department of Neurology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
4Department of Medical Imaging, Nanfang Hospital, Southern Medical University, Guangzhou, China
Download: PDF(740 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    

Mitochondrial creatine kinase (MtCK) is vital in the process of mitochondrial energy metabolism, and mitochondrial dysfunction has been implicated in the pathogenesis of Parkinson’s disease (PD). Therefore, we speculated that MtCK activity could be altered in the serum of PD patients. However, no studies to date have investigated this specific topic, so we sought to investigate the serum MtCK activities among a cohort of PD patients. 50 patients with PD and 30 age-matched controls were recruited for this study. Serum ubiquitous MtCK (uMtCK) and sarcomeric MtCK (sMtCK) activities were assayed using an immunoinhibition method. Correlations between serum uMtCK/sMtCK activities and clinical features/parameters were explored in the PD group. Our study revealed a significant decrease in the uMtCK activity in the PD group when compared with the control group. No significant difference was found in the serum sMtCK activity between the PD and control groups. There was a significant correlation between serum uMtCK activities and the disease progression rate, duration, and age at onset in PD patients. While no significant relationship was found between the serum uMtCK activities and the Hoehn & Yahr stage or main non-motor symptoms scale. There was a significant decrease in the uMtCK activity in the serum of PD patients, which was associated with the rate of disease progression, duration, and age at onset of disease. Therefore, uMtCK activity in serum offers a useful clue for identification of PD biomarkers.

Keywords Parkinson’s disease      mitochondrial creatine kinase      ubiquitous mitochondrial creatine kinase      sarcomeric mitochondrial creatine kinase      mitochondrial dysfunction     
Corresponding Authors: Wang Qun,Xu Yunqi   
About author:

These authors contributed equally to this work.

Issue Date: 29 March 2018
E-mail this article
E-mail Alert
Articles by authors
Jinghui Xu
Xiaodi Fu
Mengqiu Pan
Xiao Zhou
Zhaoyu Chen
Dongmei Wang
Xiaomei Zhang
Qiong Chen
Yanhui Li
Xiaoxian Huang
Guanghui Liu
Jianjun Lu
Yan Liu
Yafang Hu
Suyue Pan
Qing Wang
Qun Wang
Yunqi Xu
Cite this article:   
Jinghui Xu,Xiaodi Fu,Mengqiu Pan, et al. Mitochondrial Creatine Kinase is Decreased in the Serum of Idiopathic Parkinson’s Disease Patients[J]. Aging and disease, 2019, 10(3): 601-610.
URL:     OR
Age (years)61.7±8.559.8±7.0
Male21 (42%)14 (46.7%)
Female29 (58%)16 (53.3%)
BMI (Kg/m2)21.1±1.820.7±1.4
H&Y stage2.5±0.8-
Disease duration (years)4.9±3.6-
Age of Onset (years)56.8±7.9-
Rate of disease progression1.0±1.0-
MDS-UPDRS Part III32.0±21.2-
Tremor dominant (%)9 (18%)-
Akinetic-rigid dominant (%)22 (44%)-
Mixed subtype (%)19 (38%)-
Constipation32 (64%)0%
Hyposmia2 9(58%)0%
Cognitive impariment8 (16%)0%
Depression and/or anxiety38 (76%)0%
Sleep disturbances36 (72%)0%
Table 1  The demographic & clinical data of the groups studied.
GroupNAgeSerum uMtCKSerum sMtCKSerum CKMB
Early PD2759.4±7.03.9±1.90.28±0.4610.4±7.3
Late PD2364.3±9.33.0±1.50.38±0.5610.1±6.0
Early control1657.6±7.35.5±1.60.31±0.429.7±5.5
Late control1462.4±5.86.4±2.00.38±0.579.5±5.6
p-value (age adjusted)
PD vs. controls0.32<0.01**0.730.16
M:F (PD)0.580.540.860.85
M:F (C)
PD subtypeTD960.9±4.83.3±1.6
Mixed subtype1962.0±9.23.5±2.0
p-value (age adjusted)0.950.27
Drug usedWith Medopa4462.4±8.73.5±1.8
Without Medopa656.5±3.63.4±2.3
p-value (age adjusted)0.110.91
Table 2  The serum uMtCK, sMtCK, CK-MB activity, BMI in different groups.
Figure 1.  sMtCK and uMtCK activities are shown using anti-sMtCK and anti-uMtCK antibodies, respectively

Key: Log transformation was performed on concentration (X axis) of actual dose (-2=lg 0.01, -1=lg 0. 1, 0=lg 1, 1=lg 10, 2=lg 100). A preliminary study confirmed 20 µg/ml was the optimal concentration of the anti-MtCK antibody for serum measurements. uMtCK = ubiquitous Mitochondrial Creatine Kinase, sMtCK = sarcomeric Mitochondrial Creatine Kinase.

Figure 2.  Comparisons of serum activities of uMtCK and sMtCK between the different patient groups

A) The PD group had a significantly lower serum uMtCK activity when compared with controls (p<0.01). B, C) Stratified analysis was performed according to disease severity (H&Y stage), revealing a significant decrease in serum uMtCK activity between the EP and EC groups (p<0.01) as well as the LP and LC groups (p<0.01). D) No significant difference in serum sMtCK activity was observed between the PD and control groups (p=0.73).

Figure 3.  Correlation between serum uMtCK activities and rate of disease progression, disease duration, age of onset, H&Y stage, and MNMSS in PD patients

Serum uMtCK activities significantly increased along with the accelerating rate of disease progression (R2=0.233, t=3.676, p=0.001), as well as with older age of onset (R2=0.150, t=2.775, p=0.008), but significantly decreased along with extended disease duration (R2=0.160, t=-2.882, p=0.006) (A-C). No significant correlation was observed between serum uMtCK activities and either H&Y stage or MNMSS (D, E) or between serum sMtCK activities and BMI (F).

Figure 4.  ROC curve of serum uMtCK activity

The area under the curve (AUC) was 0.83 (P<0.01) (95% CI: 0.74 - 0.92). When the uMtCK activity was less than 4.37 U/L, Youden’s index was maximal with a sensitivity of 74.00% (95% CI: 59.66-85.37%) and a specificity of 90.00% (95% CI: 73.47-97.89%). ROC= receiver operator characteristic.

[1] Schipper HM (2004). Brain iron deposition and the free radical-mitochondrial theory of ageing. Ageing Research Reviews, 3:265-301.
[2] Bose A, Beal MF (2016). Mitochondrial dysfunction in Parkinson’s disease. J Neurochem, 139 Suppl 1:216-231.
[3] Moon HE, Paek SH (2015). Mitochondrial Dysfunction in Parkinson’s Disease. Exp Neurobiol, 24:103-116.
[4] Abou-Sleiman PM, Muqit MM, Wood NW (2006). Expanding insights of mitochondrial dysfunction in Parkinson’s disease. Nat Rev Neurosci, 7:207-219.
[5] Schapira AH (2013). Recent developments in biomarkers in Parkinson disease. Curr Opin Neurol, 26:395-400.
[6] Schlattner U, Tokarska-Schlattner M, Wallimann T (2006). Mitochondrial creatine kinase in human health and disease. Biochimica Et Biophysica Acta-Molecular Basis of Disease, 1762:164-180.
[7] Boero J, Qin W, Cheng J, Woolsey TA, Strauss AW, Khuchua Z (2003). Restricted neuronal expression of ubiquitous mitochondrial creatine kinase: changing patterns in development and with increased activity. Mol Cell Biochem, 244:69-76.
[8] Payne RM, Strauss AW (1994). Expression of the mitochondrial creatine kinase genes. Mol Cell Biochem, 133-134:235-243.
[9] Saks V, Guzun R, Timohhina N, Tepp K, Varikmaa M, Monge C, et al. (2010). Structure-function relationships in feedback regulation of energy fluxes in vivo in health and disease: mitochondrial interactosome. Biochim Biophys Acta, 1797:678-697.
[10] Speer O, Back N, Buerklen T, Brdiczka D, Koretsky A, Wallimann T, et al. (2005). Octameric mitochondrial creatine kinase induces and stabilizes contact sites between the inner and outer membrane. Biochemical Journal, 385:445-450.
[11] Streijger F, Oerlemans F, Ellenbroek BA, Jost CR, Wieringa B, Van der Zee CE (2005). Structural and behavioural consequences of double deficiency for creatine kinases BCK and UbCKmit. Behav Brain Res, 157:219-234.
[12] Zhang SF, Hennessey T, Yang L, Starkova NN, Beal MF, Starkov AA (2011). Impaired brain creatine kinase activity in Huntington’s disease. Neurodegener Dis, 8:194-201.
[13] Van Laar VS, Dukes AA, Cascio M, Hastings TG (2008). Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiol Dis, 29:477-489.
[14] Takubo H, Shimoda-Matsubayashi S, Mizuno Y (2003). Serum creatine kinase is elevated in patients with Parkinson’s disease: a case controlled study. Parkinsonism Relat Disord, 9 Suppl 1:S43-46.
[15] Vassilopoulos D, Jockers-Wretou E (1987). Serum creatine kinase B levels in diseases of the central nervous system. Eur Neurol, 27:78-81.
[16] Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. (2015). MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord, 30:1591-1601.
[17] Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. (2008). Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord, 23:2129-2170.
[18] Chaudhuri KR, Pal S, DiMarco A, Whately-Smith C, Bridgman K, Mathew R, et al. (2002). The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry, 73:629-635.
[19] Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, et al. (2007). The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: Results from an international pilot study. Movement Disorders, 22:1901-1911.
[20] Ozcan T, Benli E, Demir EY, Ozer F, Kaya Y, Haytan CE (2015). The relation of sexual dysfunction to depression and anxiety in patients with Parkinson’s disease. Acta Neuropsychiatr, 27:33-37.
[21] Cui GH, Yao YH, Xu RF, Tang HD, Jiang GX, Wang Y, et al. (2011). Cognitive impairment using education-based cutoff points for CMMSE scores in elderly Chinese people of agricultural and rural Shanghai China. Acta Neurologica Scandinavica, 124:361-367.
[22] Muilwijk D, Verheij S, Pel JJ, Boon AJ, van der Steen J (2013). Changes in Timing and kinematics of goal directed eye-hand movements in early-stage Parkinson’s disease. Transl Neurodegener, 2:1.
[23] Hoshino T, Sakai Y, Yamashita K, Shirahase Y, Sakaguchi K, Asaeda A, et al. (2009). Development and performance of an enzyme immunoassay to detect creatine kinase isoenzyme MB activity using anti-mitochondrial creatine kinase monoclonal antibodies. Scand J Clin Lab Invest, 69:687-695.
[24] Spinazzi M, Casarin A, Pertegato V, Salviati L, Angelini C (2012). Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells. Nature Protocols, 7:1235-1246.
[25] Hattori N, Arano T, Hatano T, Mori A, Imai Y (2017). Mitochondrial-Associated Membranes in Parkinson’s Disease. Adv Exp Med Biol, 997:157-169.
[26] Soroida Y, Ohkawa R, Nakagawa H, Satoh Y, Yoshida H, Kinoshita H, et al. (2012). Increased activity of serum mitochondrial isoenzyme of creatine kinase in hepatocellular carcinoma patients predominantly with recurrence. J Hepatol, 57:330-336.
[27] Hattori N, Tanaka M, Ozawa T, Mizuno Y (1991). Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson’s disease. Ann Neurol, 30:563-571.
[28] Flones IH, Fernandez-Vizarra E, Lykouri M, Brakedal B, Skeie GO, Miletic H, et al. (2017). Neuronal complex I deficiency occurs throughout the Parkinson’s disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage. Acta Neuropathol.
[29] Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990). Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem, 54:823-827.
[30] Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003). Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging, 24:197-211.
[31] Surmeier DJ, Obeso JA, Halliday GM (2017). Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci, 18:101-113.
[32] Fritz-Wolf K, Schnyder T, Wallimann T, Kabsch W (1996). Structure of mitochondrial creatine kinase. Nature, 381:341-345.
[33] Uranbileg B, Enooku K, Soroida Y, Ohkawa R, Kudo Y, Nakagawa H, et al. (2014). High ubiquitous mitochondrial creatine kinase expression in hepatocellular carcinoma denotes a poor prognosis with highly malignant potential. Int J Cancer, 134:2189-2198.
[34] Pak K, Shin HK, Kim EJ, Lee JH, Lyoo CH, Son J, et al. (2018). Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson’s disease. Parkinsonism Relat Disord.
[35] Cumming K, Macleod AD, Myint PK, Counsell CE (2017). Early weight loss in parkinsonism predicts poor outcomes: Evidence from an incident cohort study. Neurology, 89:2254-2261.
[36] Wills AM, Perez A, Wang J, Su X, Morgan J, Rajan SS, et al. (2016). Association Between Change in Body Mass Index, Unified Parkinson’s Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease: Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term Study 1. JAMA Neurol, 73:321-328.
[1] Murtha Lucy A., Morten Matthew, Schuliga Michael J., Mabotuwana Nishani S., Hardy Sean A., Waters David W., Burgess Janette K., Ngo Doan TM., Sverdlov Aaron L., Knight Darryl A., Boyle Andrew J.. The Role of Pathological Aging in Cardiac and Pulmonary Fibrosis[J]. Aging and disease, 2019, 10(2): 419-428.
[2] Yong-Fei Zhao, Qiong Zhang, Jian-Feng Zhang, Zhi-Yin Lou, Hen-Bing Zu, Zi-Gao Wang, Wei-Cheng Zeng, Kai Yao, Bao-Guo Xiao. The Synergy of Aging and LPS Exposure in a Mouse Model of Parkinson’s Disease[J]. Aging and disease, 2018, 9(5): 785-797.
[3] De Lazzari Federica, Bubacco Luigi, Whitworth Alexander J, Bisaglia Marco. Superoxide Radical Dismutation as New Therapeutic Strategy in Parkinson’s Disease[J]. Aging and disease, 2018, 9(4): 716-728.
[4] Eckert Schamim H, Gaca Janett, Kolesova Nathalie, Friedland Kristina, Eckert Gunter P, Muller Walter E. Mitochondrial Pharmacology of Dimebon (Latrepirdine) Calls for a New Look at its Possible Therapeutic Potential in Alzheimer’s Disease[J]. Aging and disease, 2018, 9(4): 729-744.
[5] Zhang Li, Hao Junwei, Zheng Yan, Su Ruijun, Liao Yajin, Gong Xiaoli, Liu Limin, Wang Xiaomin. Fucoidan Protects Dopaminergic Neurons by Enhancing the Mitochondrial Function in a Rotenone-induced Rat Model of Parkinson’s Disease[J]. Aging and disease, 2018, 9(4): 590-604.
[6] Perez-Roca Laia, Adame-Castillo Cristina, Campdelacreu Jaume, Ispierto Lourdes, Vilas Dolores, Rene Ramon, Alvarez Ramiro, Gascon-Bayarri Jordi, Serrano-Munoz Maria A., Ariza Aurelio, Beyer Katrin. Glucocerebrosidase mRNA is Diminished in Brain of Lewy Body Diseases and Changes with Disease Progression in Blood[J]. Aging and disease, 2018, 9(2): 208-219.
[7] Zhang Meng, Deng Yong-Ning, Zhang Jing-Yi, Liu Jie, Li Yan-Bo, Su Hua, Qu Qiu-Min. SIRT3 Protects Rotenone-induced Injury in SH-SY5Y Cells by Promoting Autophagy through the LKB1-AMPK-mTOR Pathway[J]. Aging and disease, 2018, 9(2): 273-286.
[8] Sun Qian, Wang Tian, Jiang Tian-Fang, Huang Pei, Wang Ying, Xiao Qin, Liu Jun, Chen Sheng-Di. Clinical Profile of Chinese Long-Term Parkinson’s Disease Survivors With 10 Years of Disease Duration and Beyond[J]. Aging and disease, 2018, 9(1): 8-16.
[9] Lv Deyong, Li Jingbo, Li Hongfu, Fu Yu, Wang Wei. Imaging and Quantitative Analysis of the Interstitial Space in the Caudate Nucleus in a Rotenone-Induced Rat Model of Parkinson’s Disease Using Tracer-based MRI[J]. Aging and disease, 2017, 8(1): 1-6.
[10] Su Ruijun, Sun Min, Wang Wei, Zhang Jianliang, Zhang Li, Zhen Junli, Qian Yanjing, Zheng Yan, Wang Xiaomin. A Novel Immunosuppressor, (5R)-5-Hydroxytriptolide, Alleviates Movement Disorder and Neuroinflammation in a 6-OHDA Hemiparkinsonian Rat Model[J]. Aging and disease, 2017, 8(1): 31-43.
[11] Smirnova Natalya A., Kaidery Navneet Ammal, Hushpulian Dmitry M., Rakhman Ilay I., Poloznikov Andrey A., Tishkov Vladimir I., Karuppagounder Saravanan S., Gaisina Irina N., Pekcec Anton, Leyen Klaus Van, Kazakov Sergey V., Yang Lichuan, Thomas Bobby, Ratan Rajiv R., Gazaryan Irina G.. Bioactive Flavonoids and Catechols as Hif1 and Nrf2 Protein Stabilizers - Implications for Parkinson’s Disease[J]. Aging and disease, 2016, 7(6): 745-762.
[12] Sterling Nicholas W., Lichtenstein Maya, Lee Eun-Young, Lewis Mechelle M., Evans Alicia, Eslinger Paul J., Du Guangwei, Gao Xiang, Chen Honglei, Kong Lan, Huang Xuemei. Higher Plasma LDL-Cholesterol is Associated with Preserved Executive and Fine Motor Functions in Parkinson’s Disease[J]. Aging and disease, 2016, 7(3): 237-245.
[13] Sun Qian, Wang Tian, Jiang Tian-Fang, Huang Pei, Li Dun-Hui, Wang Ying, Xiao Qin, Liu Jun, Chen Sheng-Di. Effect of a Leucine-rich Repeat Kinase 2 Variant on Motor and Non-motor Symptoms in Chinese Parkinson’s Disease Patients[J]. Aging and disease, 2016, 7(3): 230-236.
[14] Claassen Daniel O., Dobolyi David G., Isaacs David A., Roman Olivia C., Herb Joshua, Wylie Scott A., Neimat Joseph S., Donahue Manus J., Hedera Peter, Zald David H., Landman Bennett A., Bowman Aaron B., Dawant Benoit M., Rane Swati. Linear and Curvilinear Trajectories of Cortical Loss with Advancing Age and Disease Duration in Parkinson’s Disease[J]. Aging and disease, 2016, 7(3): 220-229.
[15] Redmann Matthew, Darley-Usmar Victor, Zhang Jianhua. The Role of Autophagy, Mitophagy and Lysosomal Functions in Modulating Bioenergetics and Survival in the Context of Redox and Proteotoxic Damage: Implications for Neurodegenerative Diseases[J]. Aging and disease, 2016, 7(2): 150-162.
Full text



Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail:
Powered by Beijing Magtech Co. Ltd